5 line items for oxybutynin tablets. Awarded for a base year and 4 one-year option periods.

Ended Indefinite Delivery Contract Awarded Last action

Contract number
36E79721D0025
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 100% complete
IDV ceiling
$24,778,012.45
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

Avkare LLC was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs National Acquisition Center on May 9, 2021, for the supply of Oxybutynin tablets across five line items. The contract carries a ceiling value of approximately $24.8 million and operates on a base year plus four one-year option periods structure, with an ultimate completion date of May 8, 2026. This civilian agency contract was not subject to small business set-aside restrictions, enabling unrestricted competition. The contract was solicited as a pre-solicitation opportunity posted on November 25, 2020, with a due date of December 17, 2020, prior to the formal award announcement. Oxybutynin is a generic anticholinergic medication commonly used within the Department of Veterans Affairs healthcare system for the treatment of overactive bladder and related urological conditions, making this supply agreement critical to supporting the agency's pharmaceutical inventory management and patient care delivery requirements.

The contract structure functions as a blanket purchasing agreement enabling the Department of Veterans Affairs to issue delivery orders for Oxybutynin tablets as operational needs arise throughout the contract performance period. Avkare LLC's selection reflects the company's established capability as a pharmaceutical and medical supply distributor with extensive experience fulfilling federal healthcare agency requirements, supported by its substantial portfolio of existing Indefinite Delivery Contracts with the Department of Veterans Affairs and other federal healthcare organizations. A modification issued under this contract incorporated Avkare's 2026 subcontracting plan effective January 1 through December 31, 2026, demonstrating ongoing compliance with federal subcontracting requirements during the final year of the base and option period structure. The contract award follows standard Department of Veterans Affairs pharmaceutical prime vendor procurement practices designed to ensure reliable supply chain access to generic medications supporting the department's mission of delivering healthcare services to eligible veterans.

Transactions

Action Obligated Date
Add Subcontract Plan P00012 · This modification is issued to incorporate avkare's 2026 subcontracting plan effective for the period of january 1, 2026 - december 31, 2026. $0
Exercise an Option P00011 · Exercising option year 4 for oxybutynin tablets with no price changes. Period of performance for the 4TH option year is 05/09/2025 - 05/08/2026. $0
Add Subcontract Plan P00010 · This modification is issued to incorporate avkare's 2025 subcontracting plan effective for the period of january 1, 2025 - december 31, 2025. $0
Exercise an Option P00009 · Exercising option year 3 for oxybutynin tablets with no price changes. Period of performance for the 3RD option year is 05/09/2024 - 05/08/2025. $0
Supplemental Agreement for work within scope P00008 · Modification for the supplemental changes to the CRF payment submittal and sales reporting requirements. $0
Add Subcontract Plan P00007 · This modification is issued to incorporate avkare's 2024 subcontracting plan effective for the period of january 1, 2024 - december 31, 2024. $0
Other Administrative Action P00006 · Unilateral modification is issued to incorporate updated dscsa language and requirements into VA national contract 36E79721D0025. $0
Exercise an Option P00005 · Exercising option year 2 for oxybutynin tablets with no price changes. Period of performance for the 2ND option year is 05/09/2023 - 05/08/2024. $0
Add Subcontract Plan P00004 · Far 52.219-9 small business subcontracting plan. Implement avkare, LLC 2023 subk plan. $0
Exercise an Option P00003 · Exercising option year 1 for oxybutynin tablets with price changes on all 5 line items. Period of performance for the 1ST option year is 05/09/2022 -… $0
Add Subcontract Plan P00002 · Incorporate subk plan from 01/01/2022 - 12/31/2022 into 36E79721D0025 for oxybutyinin CL tablets. $0
Other Administrative Action P00001 · Change vendor POC from KIM bracey to kala holland (administrative POC) and tommy harville (sales POC). $0
Original award $0
Show all 13

Quick answers

Who was awarded contract 36E79721D0025?

36E79721D0025 was awarded to Avkare LLC by National Acquisition Center (Headquarters) on May 9, 2021.

How much is contract 36E79721D0025 worth?

36E79721D0025's own ceiling is $24,778,012.

Who can order from contract 36E79721D0025?

36E79721D0025 is a single award indefinite delivery contract.

Was contract 36E79721D0025 competed?

The extent of competition for 36E79721D0025 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login